Addressing Endometriosis with Your Patients: Combining Individualized Treatment Options with Patient-Clinician Dialogue

Similar documents
Combining Individualized Treatment Options with Patient-Clinician Dialogue

Orilissa (elagolix) NEW PRODUCT SLIDESHOW

MANAGEMENT OF REFRACTORY ENDOMETRIOSIS

ORILISSA (elagolix) oral tablet

1. During the follicular phase of the ovarian cycle, the hypothalamus releases GnRH.

Before beginning this activity, be sure to review the faculty and commercial support disclosures, as well as the Learning Objectives.

Chapter 14 Reproduction Review Assignment

ENDOMETRIOSIS 3-MONTH TRACKER

10.7 The Reproductive Hormones

HORMONES & REPRODUCTION OUTLINE

REPRODUCTION & GENETICS. Hormones

Infertility: Current Testing and Treatment Methods

Hormonal Control of Human Reproduction

Sample Provincial exam Q s: Reproduction

Results of implication of aromatase inhibitors in therapy of genital endometriosis Yarmolinskaya M. (Speaker), Bezhenar V., Molotkov A.

Drug Therapy Guidelines

Drug Therapy Guidelines

Dr Mary Birdsall. Fertility Associates Auckland

9.4 Regulating the Reproductive System

Summary A LOOK AT ELAGOLIX FOR ENDOMETRIOSIS JULY 2018

CY Tse, AMK Chow, SCS Chan. Introduction

Agonist versus antagonist in ICSI cycles: a randomized trial and cost effectiveness analysis Badrawi A, Zaki S, Al-Inany H, Ramzy A M, Hussein M

LOW RESPONDERS. Poor Ovarian Response, Por

Investigation: The Human Menstrual Cycle Research Question: How do hormones control the menstrual cycle?

Reproductive Health and Pituitary Disease

Orgalutran 0.25 mg/0.5 ml solution for injection 2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Principles of Ovarian Stimulation

Gonadotropin Releasing Hormone (GnRH) Analogs Drug Class Prior Authorization Protocol

Chronic Pelvic Pain Case Study

PDF hosted at the Radboud Repository of the Radboud University Nijmegen

Cynthia Morris DO, FACOOG, FACOS Medical Director, Women s Wellness Center Fayette County Memorial Hospital

CONTROLLED OVARIAN HYPERSTIMULATION AND OOCYTE RETRIEVAL : CLINICAL INPUTS. DR Priyanka Sinha MD OB-GYN MUMBAI, INDIA

Difference Between PCOS and Endometriosis

Endometriosis. *Chocolate cyst in the ovary

Endometriosis. Assoc.Prof.Pawin Puapornpong, Faculty of Medicine, Srinakharinwirot University.

Assisted Reproductive Technology (ART) / Infertility / Synarel (nafarelin)

Study Guide Answer Key Reproductive System

Reproductive hormones and epilepsy

Progesterone and clinical outcomes

Reproduction and Development. Female Reproductive System

Reproductive Testing: Less is More G. Wright Bates, Jr., M.D. Professor and Director Reproductive Endocrinology and Infertility Objectives

CLEAR COVERAGE HYSTERECTOMY CHECKLISTS

MULTIPLE CHOICE: match the term(s) or description with the appropriate letter of the structure.

Reproductive Hormones

Understanding Infertility, Evaluations, and Treatment Options

Milder is better? Advantages and disadvantages of "mild" ovarian stimulation for human in vitro fertilization

Is it the seed or the soil? Arthur Leader, MD, FRCSC

First you must understand what is needed for becoming pregnant?

Ivf day 6 estradiol level

UW MEDICINE PATIENT EDUCATION. Acromegaly Symptoms and treatments. What is acromegaly? DRAFT. What are the symptoms? How is it diagnosed?

Endometriosis Information Leaflet

Palm Beach Obstetrics & Gynecology, PA

A multi-centre, multinational, cross-sectional, incident case control study on Factors associated with the development of

I. ART PROCEDURES. A. In Vitro Fertilization (IVF)

Infertility for the Primary Care Provider

POTION OR POISON? MEDICAL TREATMENT ALTERNATIVES TO THE PILL. Lester Ruppersberger, D.O., FACOOG,CNFPI NFP only Gynecologist

Moneli Golara Consultant Obstetrician and Gynaecologist Barnet Hospital Royal Free NHS Trust

Course: Animal Production. Instructor: Ms. Hutchinson. Objectives: After completing this unit of instruction, students will be able to:

Reproductive physiology

Luteal phase rescue after GnRHa triggering Progesterone and Estradiol

Female Reproductive System. Lesson 10

Manish Banker. Declared receipt of grants; member of a company advisory board, board of director or similar group

Drug Class Monograph

Animal and Veterinary Science Department University of Idaho. REGULATION OF REPRODUCTION AVS 222 (Instructor: Dr. Amin Ahmadzadeh) Chapter 5

CASE 41. What is the pathophysiologic cause of her amenorrhea? Which cells in the ovary secrete estrogen?

IVF Protocols: Hyper & Hypo-Responders, Implantation

5/5/2010. Infertility FINANCIAL DISCLOSURE. Infertility Definition. Objectives. Normal Human Fertility. Normal Menstrual Cycle

Sex Chromosomes Polygenic Trait

Infertility: failure to conceive within one year of unprotected regular sexual intercourse. Primary secondary

Endometriosis. A Guide for Patients PATIENT INFORMATION SERIES

The beginning of puberty is marked by the progressive increase in the production of sex hormones.

Dipartimento di Neuroscienze, Scienze Riproduttive ed Odontostomatologiche. Tecniche di sincronizzazione ovocitaria. La sincronizzazione follicolare

Endometriosis: An Overview

Endometriosis. What you need to know. 139 Dumaresq Street Campbelltown Phone Fax

A Prospective Observational Study to Evaluate the Efficacy and Safety Profiles of Leuprorelin 3 Month Depot for the Treatment of Pelvic Endometriosis

Web Activity: Simulation Structures of the Female Reproductive System

They are updated regularly as new NICE guidance is published. To view the latest version of this NICE Pathway see:

Endocrine Glands. Endocrine glands

Contraception. Objectives. Unintended Pregnancy. Unintended Pregnancy in the US. What s the Impact? 10/7/2014

NEW PATIENT DATA SHEET Please complete as best you can. It is not necessary to have all information before speaking with a doctor. PATIENT INFORMATION

PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION. elagolix (as elagolix sodium) tablets 150 mg and 200 mg

Cigna Drug and Biologic Coverage Policy

WHAT IS ENDOMETRIOSIS?

lactotrophs 120 min- FSH 60 min- LH Hypothalamus GnRH pituitary Estradiol +/- Progesterone _ FSH L H Ovary Uterus Ovulation Antral follicle >2mm

Raoul Orvieto. The Chaim Sheba Medical Center Tel Hashomer, Israel. Declared no potential conflict of interest

Draft Agreed by Biosimilar Working Party (BMWP) October Adoption by CHMP for release for consultation 17 November 2011

Trelstar Depot (triptorelin)

Polycystic Ovary Syndrome HEATHER BURKS, MD OU PHYSICIANS REPRODUCTIVE MEDICINE SEPTEMBER 21, 2018

Orals,Transdermals, and Other Estrogens in the Perimenopause

Degarelix Subcutaneous Injection (Firmagon ) Treatment Guideline

SOUTH AFRICAN GUIDELINE FOR TREATMENT OF ENDOMETRIOSIS

Fertility in the 21 st Century Dr Leigh Searle

EVALUATING THE INFERTILE PATIENT-COUPLES. Stephen Thorn, MD

Phases of the Ovarian Cycle

Imvexxy (estradiol) NEW PRODUCT SLIDESHOW

Breast Cancer Risk in Patients Using Hormonal Contraception

PRODUCT INFORMATION. Pharmacotherapeutic group: anti-gonadotrophin releasing hormone; ATC code: H01CC01.

Approach to ovulation induction and superovulation in women with a history of infertility. Anatte E. Karmon, MD

LH and FSH. Women. Men. Increased LH. Decreased LH. By Ronald Steriti, ND, PhD 2011

Transcription:

Addressing Endometriosis with Your Patients: Combining Individualized Treatment Options with Patient-Clinician Dialogue

Objectives Describe the multiple symptoms of endometriosis and its varied presentation among patients including pelvic pain mapping Collaborate with patients to make a more timely clinical diagnosis of endometriosis and refer patients to specialists if needed Include patients symptoms, preferences, and values to identify and select the best available treatment options for management of endometriosis symptoms and disease

Faculty Information Stephen M. Cohen, MD, FACOG Faculty SUNY Upstate Medical School Syracuse, NY Dr. Cohen receives consulting fees from AbbVie.

Background Common disease Often times frustrating to both patients and providers Limited treatments Plays a big role in patients lives Affects women s personal relationships and physical condition Need to discuss treatment options with patients

Endometriosis Chronic disease of reproductive age women Stimulated by estrogen 10% prevalence 70-80% of women who present with pain/infertility (after other causes excluded) Diagnosis often delayed High recurrence rate following medical/surgical treatment

Current Treatment Options NSAIDs Combined oral contraceptives Often self-treat before seeing their physician Treat pharmacologically, not surgically, at least initially for most patients Evolved over the years from all patients being sent to the OR Works in many cases, especially women who experience painful periods

Current Treatment Options NSAIDs Combined oral contraceptives Often self-treat before seeing their physician Treat pharmacologically, not surgically, at least initially for most patients Evolved over the years from all patients being sent to the OR Works in many cases, especially women who experience painful periods Progesterone (oral; injectable; IUS) Administered by injection or by mouth Studies show effective in treating endometriosis for 80-90% of patients

Current Treatment Options (con t) Modified testosterone GnRH agonists (injectable; nasal) Most effective after the patient has failed the common treatments Shut down the pituitary causing estrogen levels drop; symptoms of endometriosis usually improve dramatically Do have side effects, most common is bone loss Effective but limited; max. length on label is approximately one year

Antagonist Effect: Elagolix Binds Competitively to the GnRH Receptor 1,2 Competes with endogenous GnRH for GnRH receptor occupancy in the anterior pituitary and blocks receptors upon binding, so fewer receptors are activated 1 Suppresses LH and FSH in a dose-dependent manner 1 FSH: follicle-stimulating hormone; GnRH: Gonadotropin-releasing hormone; LH: luteinizing hormone 1. Ng J, Chwalisz K, Carter DC, Klein DC, J Clin Endocrinol Metab. 2017;102(5):1683-1691. 2. Bulun SE, N Engl J Med. 2009;360(3):268-279. LH and FSH suppression begins within hours of administration* and is reversible upon discontinuation 1 Leads to decreased serum levels of the ovarian sex hormones estradiol and progesterone 1

Patient Centered Care General Listen to patient attentively: goals, fears, experiences Develop relationship of trust and teamwork Use decision aids when appropriate

Patient Centered Care (con t) Treatment risk and benefits Explain goals of therapy Personalize treatment selection Management plans should consider Symptom severity Potential for recurrence Desire for fertility Other considerations: cost, side effects, and route of administration Describe risks that are common, including feared risks Monitor for tolerance, compliance, persistence and effectiveness

Patient Cases

Case #1: Kiri Age 44 G2P2002 Med history: Motrin Medical history: negative Surgical history: C-section x 1 Laparoscopy 2009 Physical exam: normal c/o severe dysmenorrhea (7/10) Missing work 1-2 days per month No desire for fertility

Case #1 Kiri Discussion What more do we need to know: Operative findings/excision or ablation/any pain lessening and recurrence History: When did pain recur? Same type of pain? Current meds for pain? Effecting relationships? Past medical treatments? Effective or ineffective

Case #1 Kiri Discussion What more do we need to know: Operative findings/excision or ablation/any pain lessening and recurrence History: When did pain recur? Same type of pain? Current meds for pain? Effecting relationships? Past medical treatments? Effective or ineffective Exam and ultrasound findings

Case #1 Kiri Discussion What more do we need to know: Operative findings/excision or ablation/any pain lessening and recurrence History: When did pain recur? Same type of pain? Current meds for pain? Effecting relationships? Past medical treatments? Effective or ineffective Exam and ultrasound findings Patient s desires: Surgical vs. medical Medical: injectable/intrauterine/oral

Case #2: Aimee Age 23 G2P1001 Current med history: Motrin/Continuous COC s Medical history: depression Surgical history: Laparoscopy 2015 Physical exam: thickened uterosacral ligaments; decreased mobility c/o severe dysmenorrhea (7/10) and dyspareunia (8/10) Missing work 2 days per month

Case #2 Aimee Discussion What more do we need to know: Operative findings/excision or ablation/any pain lessening and recurrence History: When did pain recur? Same type of pain? Current meds for pain? Effecting relationships? Past medical treatments? Effective or ineffective Desire for maintaining fertility

Case #2 Aimee Discussion What more do we need to know: Operative findings/excision or ablation/any pain lessening and recurrence History: When did pain recur? Same type of pain? Current meds for pain? Effecting relationships? Past medical treatments? Effective or ineffective Desire for maintaining fertility Exam and ultrasound findings

Case #2 Aimee Discussion What more do we need to know: Operative findings/excision or ablation/any pain lessening and recurrence History: When did pain recur? Same type of pain? Current meds for pain? Effecting relationships? Past medical treatments? Effective or ineffective Desire for maintaining fertility Exam and ultrasound findings Patient s desires: Surgical vs. medical Medical: injectable/intrauterine/oral

Conclusions Physicians need to spend a bit more time with endometriosis patients and really listen to them The goal is for these patients to feel that they are being heard and that they work together on their treatment approach